Boston Scientific is a global medical technology company that specializes in the development, manufacturing, and marketing of a wide range of medical devices and solutions. The company focuses on providing innovative therapies for various medical conditions, including those affecting the cardiovascular, urology, and gastrointestinal systems, among others. Boston Scientific is committed to advancing patient care through its pioneering technologies, which are designed to improve outcomes and enhance the quality of life for patients around the world. Their product offerings include devices for minimally invasive procedures, enabling healthcare professionals to deliver high-quality care efficiently and effectively. Read More
Law Offices of Howard G. Smith announces an investigation on behalf of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) investors concerning the Company’s possible violations of federal securities laws.
The Law Offices of Frank R. Cruz announces an investigation of Boston Scientific Corporation (“Boston Scientific” or the “Company”) (NYSE: BSX) on behalf of investors concerning the Company’s possible violations of federal securities laws.
As of February 6, 2026, the global financial landscape is being reshaped by an unprecedented "wall of capital." After nearly two years of stagnation caused by valuation gaps and high borrowing costs, the private equity industry has entered a transformative period of deployment. With a record-shattering $3.2 trillion in
The long-awaited "deal drought" has officially broken. As of early February 2026, the American financial landscape is being reshaped by a massive resurgence in corporate deal-making, punctuated by a staggering 111.5% year-over-year increase in transactions valued over $100 million at the close of 2025. This tidal wave of capital
In a move that has sent shockwaves through the medical technology sector, Boston Scientific (NYSE:BSX) announced on January 15, 2026, a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal represents the largest acquisition for Boston Scientific in over two decades, signaling a transformative
A group of emerging biotech and healthcare companies is gaining attention as they advance novel technologies across oncology, regenerative medicine, infection prevention, and precision radiotherapy—sectors that remain top priorities for global healthcare systems and investors alike. From late-stage cancer immunotherapy programs to next-generation hygiene platforms and regenerative biologics, these five companies represent distinct but complementary approaches to addressing high-value medical needs.
The "Great Hesitation" in global finance has officially come to an end. In the opening weeks of 2026, the private equity landscape has undergone a dramatic transformation, shifting from two years of defensive posturing to a full-scale dealmaking renaissance. Driven by a record-shattering $2 trillion in "dry powder" and a
February 5, 2026 The medical technology landscape experienced a seismic shift this week as one of its long-standing titans, Boston Scientific (NYSE: BSX), faced a "valuation reset" that has left investors and analysts debating the future of high-growth medtech. For over a decade, Boston Scientific has been the gold standard for consistent execution and category [...]
Medical device company Boston Scientific (NYSE:BSX) met Wall Street’s revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to be around $5.19 billion, close to analysts’ estimates. Its non-GAAP profit of $0.80 per share was 2.4% above analysts’ consensus estimates.
Shares of medical device company Boston Scientific (NYSE:BSX)
fell 13.9% in the afternoon session after the company reported fourth-quarter 2025 results that beat Wall Street estimates but provided a mixed forecast that concerned investors.
Medical device company Boston Scientific (NYSE:BSX) met Wall Streets revenue expectations in Q4 CY2025, with sales up 15.9% year on year to $5.29 billion. The company expects next quarter’s revenue to be around $5.19 billion, close to analysts’ estimates. Its non-GAAP profit of $0.80 per share was 2.4% above analysts’ consensus estimates.
